Firefly Neuroscience Shares Double After Move to Advance BNA Platform
By Chris Wack
Firefly Neuroscience shares doubled to $3.90 Tuesday after the company said it is advancing its research used to assess a patient's brain age--an estimation of the biological age of a person's brain--via its Food and Drug Administration-cleared BNA technology platform.
The AI healthcare company said the technology demonstrated the ability to harness resting electroencephalograms and cognitive electroencephalograms data to assess patients' brain age.
Firefly said the BNA technology has the potential to show various facets of human brain aging. BNA data assessment, the company said, could find a significant disparity between brain age and chronological age, which could serve as a valuable risk factor for dementia.
Firefly said it hopes to apply the technology to early screening and monitoring for Alzheimer's patients.
Write to Chris Wack at [email protected]